Bayer Other Operating Income or Expenses 2010-2024 | BAYRY

Bayer other operating income or expenses from 2010 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
Bayer Annual Other Operating Income or Expenses
(Millions of US $)
2023 $-7,544
2022 $-381
2021 $-3,756
2020 $-17,561
2019 $-429
2018 $2,436
2017 $-95
2016 $-40
2015 $-189
2014 $-178
2013 $-960
2012 $-2,411
2011 $
2010 $
2009 $
Bayer Quarterly Other Operating Income or Expenses
(Millions of US $)
2024-06-30 $-2,551
2024-03-31 $48
2023-12-31 $-523
2023-09-30 $-4,373
2023-06-30 $-2,583
2023-03-31 $-64
2022-12-31 $240
2022-09-30 $-181
2022-06-30 $-607
2022-03-31 $166
2021-12-31 $-63
2021-09-30 $-40
2021-06-30 $-3,861
2021-03-31 $207
2020-12-31 $-473
2020-09-30 $-3,292
2020-06-30 $-13,188
2020-03-31 $-608
2019-12-31 $-1
2019-09-30 $260
2019-06-30 $-407
2019-03-31 $-282
2018-12-31 $-2,510
2018-09-30 $4,690
2018-06-30 $186
2018-03-31 $70
2017-12-31 $-167
2017-09-30 $42
2017-06-30 $27
2017-03-31 $2
2016-12-31 $-112
2016-09-30 $30
2016-06-30 $41
2016-03-31 $1
2015-12-31 $178
2015-09-30 $-42
2015-06-30 $-201
2015-03-31 $-123
2014-12-31 $-345
2014-09-30 $89
2014-06-30 $29
2014-03-31 $49
2013-12-31 $-525
2013-09-30 $-44
2013-06-30 $-303
2013-03-31 $-89
2012-12-31 $-453
2012-09-30 $-566
2012-06-30 $-1,095
2012-03-31 $-298
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $710.098B 73.55
Novo Nordisk (NVO) Denmark $471.460B 34.00
Johnson & Johnson (JNJ) United States $373.591B 15.15
AbbVie (ABBV) United States $312.696B 16.46
Merck (MRK) United States $250.889B 16.67
Novartis AG (NVS) Switzerland $213.148B 14.17
AstraZeneca (AZN) United Kingdom $203.493B 17.32
Pfizer (PFE) United States $145.358B 9.94
Sanofi (SNY) $122.526B 11.10
Innoviva (INVA) United States $1.199B 9.97